Dimension Therapeutics
Cambridge
About Dimension Therapeutics
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $124.5M
- Funding stage: M&A
- Last round: Series B (Apr 2015)
- Ticker: nasdaq:DMTX
- Website: dimensiontx.com
- Phone: +1 617-401-0011
Industries & Categories
Biotechnology, Genetics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dimension-therapeutics-1013584 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.